Antimicrobial Agents Practice Questions

Q: Which of the following is a recently approved drug for multidrug-resistant tuberculosis (MDR TB)?

Bedaquiline. **Explanation:** **Bedaquiline** is the correct answer as it is a diarylquinoline, specifically developed and recently approved for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults when an effective alternative regimen is unavailable. * **Mechanism of Action:** It inhibits the enzyme **ATP synthase** in *Mycobacterium tuberculosis*, thereby depleting the energy supply required for bacterial replication. This is a novel mechanism, distinct from older anti-TB drugs, making it effective against resistant strains. **Analysis of Incorrect Options:** * **Tipranavir:** This is a non-peptidic **Protease Inhibitor (PI)** used in the treatment of HIV/AIDS, not tuberculosis. * **Levofloxacin:** While this fluoroquinolone is a crucial component of MDR-TB regimens (Group A drug), it is an older, broad-spectrum antibiotic and not a "recently approved" specific anti-TB agent in the context of novel drug classes. * **Linezolid:** An oxazolidinone used for Gram-positive infections and MDR-TB. Like Levofloxacin, it is an established drug repurposed for TB rather than a newly developed diarylquinoline like Bedaquiline. **High-Yield Facts for NEET-PG:** 1. **Bedaquiline Side Effect:** It can cause **QT interval prolongation**. Co-administration with other QT-prolonging drugs (like Clofazimine or Moxifloxacin) requires careful monitoring. 2. **Pretomand/Delamanid:** These are other newer drugs (Nitroimidazoles) used for MDR/XDR-TB that inhibit mycolic acid synthesis. 3. **BPaL Regimen:** A modern, highly effective regimen for XDR-TB consisting of **B**edaquiline, **P**retomanid, and **L**inezolid.

Q: Which anti-tuberculosis drug leads to resistance most rapidly?

Isoniazid. **Explanation:** The development of drug resistance in *Mycobacterium tuberculosis* occurs due to spontaneous genetic mutations. Among the first-line anti-tubercular drugs (ATT), **Isoniazid (INH)** is associated with the most rapid development of resistance when used as monotherapy. **Why Isoniazid is the correct answer:** Resistance to INH occurs primarily due to mutations in the **katG gene**, which encodes the enzyme **catalase-peroxidase**. Since INH is a prodrug, it requires this enzyme for activation. A single-step mutation in katG leads to a high level of resistance. Statistically, the frequency of spontaneous mutations for INH is approximately **1 in 10⁶** bacilli, which is significantly higher than for other drugs like Rifampicin. **Analysis of Incorrect Options:** * **Rifampicin:** Resistance develops due to mutations in the **rpoB gene** (beta-subunit of RNA polymerase). The mutation frequency is much lower (**1 in 10⁸**), making it less likely to develop resistance as rapidly as INH. * **Streptomycin:** Resistance occurs via mutations in the **rpsL or rrs genes** (ribosomal proteins). While resistance can develop, it is generally slower and less frequent than INH in a clinical population. * **Ethambutol:** Resistance develops due to mutations in the **embB gene** (arabinosyl transferase). It is a bacteriostatic drug with a relatively low rate of primary resistance compared to INH. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** INH inhibits **Mycolic acid synthesis**; Rifampicin inhibits **DNA-dependent RNA polymerase**. * **MDR-TB Definition:** Resistance to at least **Isoniazid and Rifampicin**. * **XDR-TB Definition:** MDR-TB plus resistance to any **Fluoroquinolone** and at least one **second-line injectable** (Amikacin, Kanamycin, or Capreomycin). * **Prophylaxis:** INH is the drug of choice for latent TB and chemoprophylaxis in HIV-positive patients or household contacts of open TB cases.

Q: Which drug commonly causes orange-colored urine?

Rifampicin. **Explanation:** **Rifampicin** is the correct answer. It is a macrocyclic antibiotic used as a first-line agent in the treatment of Tuberculosis. The drug is a zwitterionic compound with a distinct reddish-orange pigment. After administration, it is widely distributed in body fluids and excreted via the liver and kidneys [1]. This results in a **harmless, reddish-orange discoloration** of urine, sweat, tears, saliva, and even contact lenses [3]. **Analysis of Incorrect Options:** * **B. Isoniazid (INH):** Its primary side effects are peripheral neuropathy (prevented by Pyridoxine/Vitamin B6) and hepatotoxicity [2]. It does not cause pigment changes in body fluids. * **C. Ethambutol:** The hallmark side effect is optic neuritis, leading to decreased visual acuity and red-green color blindness. It is the only bacteriostatic drug among the first-line anti-tubercular agents. * **D. Pyrazinamide:** Most commonly associated with hyperuricemia (which may precipitate gout) and hepatotoxicity [4]. It does not cause orange urine. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Rifampicin inhibits **DNA-dependent RNA polymerase**, thereby blocking bacterial RNA synthesis [2]. * **Enzyme Induction:** Rifampicin is a potent **Cytochrome P450 inducer**, which leads to numerous drug interactions (e.g., reducing the efficacy of oral contraceptives and warfarin). * **Patient Counseling:** Always advise patients that orange urine is a benign side effect to ensure treatment compliance and prevent unnecessary alarm. * **Other drugs causing orange urine:** Sulfasalazine and Phenazopyridine.

Q: A 30-year-old pregnant woman develops tuberculosis. Which of the following antitubercular drugs should not be used?

Streptomycin. **Explanation:** The correct answer is **Streptomycin** because it is a member of the aminoglycoside class, which is known to be **ototoxic and nephrotoxic**. In pregnancy, Streptomycin crosses the placental barrier and can cause **permanent bilateral congenital deafness** (CN VIII damage) in the fetus. Consequently, it is classified as FDA Pregnancy Category D and is generally contraindicated unless no other alternatives exist. **Analysis of Options:** * **Isoniazid (INH):** Considered safe in pregnancy. However, due to the increased risk of peripheral neuropathy in pregnant women, it must be co-administered with **Pyridoxine (Vitamin B6)**. * **Rifampicin:** Considered safe and is a core component of the RNTCP/WHO regimen for pregnant women. It has no documented teratogenic effects in humans at standard doses. * **Ethambutol:** Considered the safest of the first-line antitubercular drugs during pregnancy; it does not cross the placenta in significant amounts to cause fetal ocular toxicity. **NEET-PG High-Yield Pearls:** 1. **Standard Regimen:** The WHO and National Guidelines recommend the standard 6-month 2HRE/4HR regimen for pregnant women. **Pyrazinamide** is also now considered safe and included in the intensive phase. 2. **Vitamin B6:** Always supplement INH with 10–25 mg/day of Pyridoxine in pregnancy to prevent maternal neuropathy and fetal seizures. 3. **Contraindicated Drugs:** Avoid **Streptomycin** (Ototoxicity), **Ethionamide** (Teratogenic), and **Fluoroquinolones** (Cartilage damage/Arthropathy) during pregnancy. 4. **Breastfeeding:** All first-line ATT drugs are compatible with breastfeeding as they occur in negligible concentrations in breast milk.

Q: DNA dependent RNA synthesis is inhibited by which of the following agents?

Rifampicin. **Explanation:** **Correct Answer: A. Rifampicin** Rifampicin is a bactericidal antibiotic that acts by inhibiting the **DNA-dependent RNA polymerase** enzyme. It binds to the beta-subunit of this enzyme, preventing the initiation of mRNA synthesis (transcription). This specific mechanism makes it a cornerstone in the treatment of Tuberculosis and Leprosy. **Analysis of Incorrect Options:** * **B. Ethambutol:** This is an anti-tubercular drug that inhibits **arabinosyl transferase**, an enzyme essential for the synthesis of arabinogalactan in the mycobacterial cell wall. * **C. Colchicine:** Used primarily in gout, colchicine acts by binding to **tubulin**, inhibiting microtubule polymerization and interfering with neutrophil motility and chemotaxis. It does not affect RNA synthesis. * **D. Chloromycetin (Chloramphenicol):** This is a bacteriostatic antibiotic that inhibits protein synthesis by binding to the **50S ribosomal subunit**, preventing the action of peptidyl transferase. **High-Yield Clinical Pearls for NEET-PG:** * **Resistance:** Resistance to Rifampicin develops due to mutations in the **rpoB gene** (which encodes the beta-subunit of RNA polymerase). * **Side Effects:** A classic "exam favorite" side effect is the **orange-red discoloration** of body fluids (urine, sweat, tears). It is also a potent **microsomal enzyme inducer** (CYP450), leading to numerous drug interactions (e.g., reducing the efficacy of oral contraceptives and warfarin). * **Other RNA Polymerase Inhibitors:** **Fidaxomicin** (used for *C. difficile*) also inhibits RNA polymerase, but at a different site than Rifampicin.

Q: Which of the following drugs is not used in the treatment of multibacillary leprosy as per the recommendations of the World Health Organization?

Minocycline. **Explanation:** The World Health Organization (WHO) recommends a standardized **Multi-Drug Therapy (MDT)** regimen for the treatment of leprosy to prevent the emergence of drug resistance. **Why Minocycline is the correct answer:** While Minocycline possesses significant bactericidal activity against *Mycobacterium leprae*, it is considered a **second-line drug**. It is not part of the standard WHO-recommended MDT for Multibacillary (MB) leprosy. It is primarily used in alternative regimens for patients who cannot tolerate first-line drugs or in the ROM (Rifampicin, Ofloxacin, Minocycline) regimen for Single Lesion Paucibacillary leprosy. **Analysis of incorrect options:** * **A. Rifampicin:** The most potent bactericidal component of the MDT. In MB leprosy, it is administered as a supervised monthly dose of 600 mg. * **B. Clofazimine:** A dye with weak bactericidal and anti-inflammatory properties. It is essential in MB leprosy to prevent the development of Erythema Nodosum Leprosum (ENL) and is given as a 300 mg monthly supervised dose and 50 mg daily self-administered dose. * **C. Dapsone:** A bacteriostatic drug that inhibits folate synthesis. It is a core component of the MDT, administered as a 100 mg daily dose. **High-Yield Clinical Pearls for NEET-PG:** * **WHO MB-MDT Regimen:** Rifampicin (600mg/month), Clofazimine (300mg/month + 50mg/day), and Dapsone (100mg/day) for a total duration of **12 months**. * **Uniform MDT (U-MDT):** Recent WHO guidelines suggest a 6-month regimen of the same three drugs for both PB and MB leprosy to simplify logistics. * **Side Effects:** Clofazimine causes brownish-black skin discoloration; Dapsone can cause hemolysis (especially in G6PD deficiency) and "Dapsone Syndrome."

Q: Which antibiotic can be safely administered to pregnant women?

Cefuroxime. **Explanation:** The safety of drugs during pregnancy is categorized by the FDA. The correct answer is **Cefuroxime**, a second-generation cephalosporin. **1. Why Cefuroxime is correct:** Cephalosporins (along with Penicillins and Erythromycin) are classified as **FDA Category B**. They do not have documented teratogenic effects in humans and are considered the "drugs of choice" for treating bacterial infections during pregnancy. Cefuroxime is safe for treating respiratory tract infections and UTIs in pregnant patients. **2. Why the other options are incorrect:** * **Ciprofloxacin (Option A):** This is a Fluoroquinolone. These are generally avoided in pregnancy because they have a high affinity for bone and cartilage, potentially causing **arthropathy** and permanent cartilage damage in the developing fetus. * **Metronidazole (Option C):** While often used after the first trimester for specific indications, it is traditionally avoided in the **first trimester** due to theoretical concerns regarding mutagenicity (though human data is reassuring, it remains less "safe" than Cephalosporins). * **Chloramphenicol (Option D):** It is contraindicated, especially near term. It can lead to **Gray Baby Syndrome** in neonates because their immature livers cannot conjugate the drug via glucuronidation, leading to toxic accumulation and cardiovascular collapse. **Clinical Pearls for NEET-PG:** * **Safe Antibiotics (CAMP):** **C**ephalosporins, **A**moxicillin/Ampicillin, **M**acrolides (except Estolate form), and **P**enicillins. * **Teratogenic Antibiotics to remember:** * **Tetracyclines:** Discolored teeth and inhibited bone growth. * **Aminoglycosides:** Ototoxicity (CN VIII damage). * **Sulfonamides:** Kernicterus (if given near term). * **Nitrofurantoin:** Hemolysis if the fetus is G6PD deficient.

Q: Which of the following drugs cannot be used to treat Candida infection?

Griseofulvin. **Explanation:** The correct answer is **Griseofulvin** because of its specific spectrum of activity and mechanism of action. **1. Why Griseofulvin is the correct answer:** Griseofulvin is a fungistatic drug that acts by binding to fungal microtubules, thereby inhibiting mitosis. Its clinical utility is strictly limited to **Dermatophytosis** (infections caused by *Trichophyton, Epidermophyton,* and *Microsporum*). It has **no activity** against *Candida* species or deep systemic mycoses. It is unique because it deposits in keratin precursor cells, making them resistant to fungal invasion. **2. Why the other options are incorrect:** * **Ketoconazole (Option A):** An imidazole derivative that inhibits ergosterol synthesis. It is effective against various *Candida* species, though its systemic use has largely been replaced by safer triazoles (like Fluconazole). * **Nystatin (Option B):** A polyene antibiotic similar to Amphotericin B. It is too toxic for systemic use but is a first-line agent for **topical or oral candidiasis** (thrush). * **Amphotericin B (Option C):** The "gold standard" polyene for systemic fungal infections. It binds to ergosterol in the fungal cell membrane, creating pores. It is highly effective against most *Candida* species, including those causing invasive candidemia. **High-Yield Clinical Pearls for NEET-PG:** * **Griseofulvin** is a potent **Microsomal Enzyme Inducer** (decreases Warfarin efficacy) and can trigger **disulfiram-like reactions**. * **Drug of Choice (DOC) for Candidiasis:** Fluconazole is the DOC for most localized infections; Echinocandins (e.g., Caspofungin) are often preferred for systemic candidemia in unstable patients. * **Griseofulvin** absorption is significantly increased when taken with a **fatty meal**.

Q: Which of the following drugs is not used in the treatment of Mycobacterium avium intracellular infection?

Eflornithine. **Explanation:** The treatment of *Mycobacterium avium-intracellulare* complex (MAC) requires a multidrug regimen due to its high level of intrinsic resistance to standard antitubercular drugs. **Why Eflornithine is the correct answer:** **Eflornithine** is an antiprotozoal medication, not an antimycobacterial agent. It acts as an irreversible inhibitor of ornithine decarboxylase. Its primary clinical uses include the treatment of **African Trypanosomiasis** (Sleeping Sickness caused by *Trypanosoma brucei gambiense*) and topically to reduce unwanted facial hair (hirsutism) in women. It has no activity against MAC. **Analysis of Incorrect Options:** * **Clarithromycin (Option A):** Macrolides (Clarithromycin or Azithromycin) are the **backbone** of MAC therapy. They are used for both prophylaxis (in HIV patients with CD4 <50 cells/mm³) and active treatment. * **Ethambutol (Option C):** This is a standard component of the multidrug regimen for MAC. It is added to a macrolide to enhance efficacy and prevent the emergence of drug resistance. * **Rifabutin (Option D):** Rifabutin is preferred over Rifampin for MAC because it is more potent against the complex and has fewer drug-drug interactions with antiretroviral therapy (ART) in HIV patients. **High-Yield Clinical Pearls for NEET-PG:** * **Standard MAC Regimen:** Clarithromycin + Ethambutol + Rifabutin. * **Prophylaxis:** Indicated in HIV patients when CD4 count falls below **50 cells/mm³**. * **Eflornithine Mnemonic:** "Resurrection drug" for African Sleeping Sickness (coma stage). * **Rifabutin Side Effect:** Watch for **uveitis** and orange discoloration of secretions.

Question 1

A patient taking an oral sulfonamide develops markedly decreased peripheral blood neutrophil count, while platelets and erythrocytes remain normal. If this neutropenia is caused by antineutrophil antibodies produced in response to the sulfonamide, what would be expected?

Accepted Answer

Hyperplasia of the bone marrow myeloid series

Answer

An atrophic spleen

Answer

Decreased vitamin B12 levels

Answer

Hypoplasia of the bone marrow myeloid series

Question 2

Which of the following is a recently approved drug for multidrug-resistant tuberculosis (MDR TB)?

Accepted Answer

Bedaquiline

Answer

Tipranavir

Answer

Levofloxacin

Answer

Linezolid

Question 3

Which anti-tuberculosis drug leads to resistance most rapidly?

Accepted Answer

Isoniazid

Answer

Streptomycin

Answer

Rifampicin

Answer

Ethambutol

Question 4

Which drug commonly causes orange-colored urine?

Accepted Answer

Rifampicin

Answer

Isoniazid

Answer

Ethambutol

Answer

Pyrazinamide

Question 5

A 30-year-old pregnant woman develops tuberculosis. Which of the following antitubercular drugs should not be used?

Accepted Answer

Streptomycin

Answer

Isoniazid (INH)

Answer

Rifampicin

Answer

Ethambutol

Question 6

DNA dependent RNA synthesis is inhibited by which of the following agents?

Accepted Answer

Rifampicin

Answer

Ethambutol

Answer

Colchicine

Answer

Chloromycetin

Question 7

Which of the following drugs is not used in the treatment of multibacillary leprosy as per the recommendations of the World Health Organization?

Accepted Answer

Minocycline

Answer

Rifampicin

Answer

Clofazimine

Answer

Dapsone

Question 8

Which antibiotic can be safely administered to pregnant women?

Accepted Answer

Cefuroxime

Answer

Ciprofloxacin

Answer

Metronidazole

Answer

Chloramphenicol

Question 9

Which of the following drugs cannot be used to treat Candida infection?

Accepted Answer

Griseofulvin

Answer

Ketoconazole

Answer

Nystatin

Answer

Amphotericin

Question 10

Which of the following drugs is not used in the treatment of Mycobacterium avium intracellular infection?

Accepted Answer

Eflornithine

Answer

Clarithromycin

Answer

Ethambutol

Answer

Rifabutin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?